ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,126.40
-0.19%
S&P ASX All Technology
3,366.70
-1.47%
Brent Oil
73.655
-1.21%
US Dollar vs AUD
1.45481
0.46%
Bitcoin
63,507.03
-1.19%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Merus NV (MRUS)

  7. Merus NV (MRUS) News

MRUS

Merus NV (MRUS)

Merus NV
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:MRUS
DateTimeSourceHeadlineSymbolCompany
17/09/202423:00GlobeNewswire Inc.Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024NASDAQ:MRUSMerus NV
23/08/202406:03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MRUSMerus NV
06/08/202422:00GlobeNewswire Inc.Merus to Present at Canaccord Genuity’s 44th Annual Growth ConferenceNASDAQ:MRUSMerus NV
02/08/202406:10GlobeNewswire Inc.Merus Announces Financial Results for the Second Quarter 2024 and Provides Business UpdateNASDAQ:MRUSMerus NV
02/08/202406:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MRUSMerus NV
24/07/202421:00GlobeNewswire Inc.Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCCNASDAQ:MRUSMerus NV
08/07/202422:00GlobeNewswire Inc.Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRCNASDAQ:MRUSMerus NV
01/07/202422:00GlobeNewswire Inc.Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical OfficerNASDAQ:MRUSMerus NV
18/06/202405:37Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MRUSMerus NV
13/06/202407:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MRUSMerus NV
07/06/202406:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MRUSMerus NV
04/06/202404:30GlobeNewswire Inc.Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual MeetingNASDAQ:MRUSMerus NV
03/06/202402:30GlobeNewswire Inc.Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual MeetingNASDAQ:MRUSMerus NV
31/05/202407:21Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:MRUSMerus NV
30/05/202411:30GlobeNewswire Inc.Merus Announces Pricing of Upsized Public Offering of Common SharesNASDAQ:MRUSMerus NV
29/05/202422:00GlobeNewswire Inc.Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare ConferenceNASDAQ:MRUSMerus NV
29/05/202406:29Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:MRUSMerus NV
29/05/202406:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRUSMerus NV
29/05/202406:01GlobeNewswire Inc.Merus N.V. Announces Proposed Public Offering of Common SharesNASDAQ:MRUSMerus NV
28/05/202421:00GlobeNewswire Inc.Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCCNASDAQ:MRUSMerus NV
24/05/202407:00GlobeNewswire Inc.Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual MeetingNASDAQ:MRUSMerus NV
13/05/202422:00GlobeNewswire Inc.Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDANASDAQ:MRUSMerus NV
11/05/202406:33Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:MRUSMerus NV
10/05/202406:35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MRUSMerus NV
10/05/202406:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MRUSMerus NV
10/05/202406:30Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:MRUSMerus NV
10/05/202406:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MRUSMerus NV
10/05/202406:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MRUSMerus NV
10/05/202406:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MRUSMerus NV
10/05/202406:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MRUSMerus NV
 Showing the most relevant articles for your search:NASDAQ:MRUS

Your Recent History

FX
AUDJPY
AUD vs Yen
NASDAQ
MSFT
Microsoft
FX
EURAUD
Euro vs AUD
COIN
DOGEUSD
Dogecoin
ASX
ORG
Origin Energy
COIN
AVAXUSD
Avalanche
ASX
NAB
National Australia Bank
NASDAQ
QQQ
Invesco QQQ Trust Series 1
ASX
WES
Wesfarmers
NASDAQ
NVDA
NVIDIA
ASX
NCM
Newcrest Mining
ASX
ANZ
Australia And New Zealan...
ASX
BHP
BHP
NYSE
MRK
Merck
COIN
BTCUSD
Bitcoin
FX
AUDCAD
AUD vs CAD
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved